Regencell Bioscience [RGC] vs Prestige Consumer [PBH] Detailed Stock Comparison
Regencell Bioscience
NASDAQ
Loading...
Prestige Consumer
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Regencell Bioscience wins in 5 metrics, Prestige Consumer wins in 9 metrics, with 0 ties. Prestige Consumer appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regencell Bioscience | Prestige Consumer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1,779.13 | 17.92 | Regencell Bioscience |
| Price-to-Book Ratio | 1,121.43 | 2.07 | Prestige Consumer |
| Debt-to-Equity Ratio | 0.00 | 56.91 | Regencell Bioscience |
| PEG Ratio | N/A | 16.12 | N/A |
| EV/EBITDA | -1,913.48 | 12.51 | Regencell Bioscience |
| Profit Margin (TTM) | 0.00% | 18.86% | Prestige Consumer |
| Operating Margin (TTM) | 0.00% | 34.03% | Prestige Consumer |
| EBITDA Margin (TTM) | N/A | 34.03% | N/A |
| Return on Equity | -47.77% | 12.30% | Prestige Consumer |
| Return on Assets (TTM) | -30.65% | 6.50% | Prestige Consumer |
| Free Cash Flow (TTM) | $-4.01M | $243.29M | Prestige Consumer |
| 1-Year Return | 14,581.82% | -8.70% | Regencell Bioscience |
| Price-to-Sales Ratio (TTM) | N/A | 3.33 | N/A |
| Enterprise Value | $7.64B | $4.75B | Regencell Bioscience |
| EV/Revenue Ratio | N/A | 4.17 | N/A |
| Gross Profit Margin (TTM) | N/A | 57.34% | N/A |
| Revenue per Share (TTM) | $0 | $23 | Prestige Consumer |
| Earnings per Share (Diluted) | $-0.01 | $4.29 | Prestige Consumer |
| Beta (Stock Volatility) | 2.15 | 0.43 | Prestige Consumer |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Regencell Bioscience vs Prestige Consumer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 2.02% | 6.67% | 25.68% | 55.89% | 2,504.84% | 12,323.08% |
| Prestige Consumer | -0.82% | 0.19% | -5.50% | -21.63% | -26.96% | -19.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 14,581.82% | 1,845.78% | 5,667.86% | 5,667.86% | 5,667.86% | 5,667.86% |
| Prestige Consumer | -8.70% | 26.31% | 69.11% | 30.16% | 500.76% | 421.49% |
News Based Sentiment: Regencell Bioscience vs Prestige Consumer
Regencell Bioscience
News based Sentiment: POSITIVE
The month of October 2025 showed positive movement in investor sentiment with a decrease in short interest and a higher-than-average news sentiment score. However, the lack of insider and institutional activity tempers the overall outlook, suggesting a need for continued monitoring.
Prestige Consumer
News based Sentiment: MIXED
September presented a mixed bag for Prestige Consumer Healthcare, with disappointing revenue figures countered by positive EPS results and strategic moves like the Pillar5 Pharma acquisition. Analyst sentiment is divided, and the stock hit a 52-week low, creating a complex investment picture that requires careful monitoring.
Performance & Financial Health Analysis: Regencell Bioscience vs Prestige Consumer
| Metric | RGC | PBH |
|---|---|---|
| Market Information | ||
| Market Cap | $7.64B | $3.79B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 183,082 | 406,280 |
| 90 Day Avg. Volume | 247,494 | 411,937 |
| Last Close | $16.15 | $62.84 |
| 52 Week Range | $0.09 - $83.60 | $61.28 - $90.04 |
| % from 52W High | -80.68% | -30.21% |
| All-Time High | $950.00 (May 30, 2025) | $90.04 (Mar 10, 2025) |
| % from All-Time High | -98.30% | -30.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.07% |
| Quarterly Earnings Growth | N/A | 0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.19% |
| Operating Margin (TTM) | 0.00% | 0.34% |
| Return on Equity (TTM) | -0.48% | 0.12% |
| Debt to Equity (MRQ) | 0.00 | 56.91 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.01 | $37.06 |
| Cash per Share (MRQ) | N/A | $1.98 |
| Operating Cash Flow (TTM) | $-3,881,392 | $251.52M |
| Levered Free Cash Flow (TTM) | $-4,301,837 | $188.69M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Regencell Bioscience vs Prestige Consumer
| Metric | RGC | PBH |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1,779.13 | 17.92 |
| Forward P/E | N/A | 16.12 |
| PEG Ratio | N/A | 16.12 |
| Price to Sales (TTM) | N/A | 3.33 |
| Price to Book (MRQ) | 1,121.43 | 2.07 |
| Market Capitalization | ||
| Market Capitalization | $7.64B | $3.79B |
| Enterprise Value | $7.64B | $4.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 4.17 |
| Enterprise to EBITDA | -1,913.48 | 12.51 |
| Risk & Other Metrics | ||
| Beta | 2.15 | 0.43 |
| Book Value per Share (MRQ) | $0.01 | $37.06 |
Financial Statements Comparison: Regencell Bioscience vs Prestige Consumer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGC | PBH |
|---|---|---|
| Revenue/Sales | N/A | $296.52M |
| Cost of Goods Sold | N/A | $126.51M |
| Gross Profit | N/A | $170.01M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | $100.89M |
| EBITDA | N/A | $91.97M |
| Pre-Tax Income | N/A | $73.96M |
| Income Tax | N/A | $23.83M |
| Net Income (Profit) | N/A | $50.13M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGC | PBH |
|---|---|---|
| Cash & Equivalents | $2.96M | $97.88M |
| Total Current Assets | $8.11M | $448.33M |
| Total Current Liabilities | $193,578 | $106.62M |
| Long-Term Debt | $25,934 | $1.04B |
| Total Shareholders Equity | $8.22M | $1.83B |
| Retained Earnings | $-21.62M | $1.56B |
| Property, Plant & Equipment | $84,780 | $53.29M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGC | PBH |
|---|---|---|
| Operating Cash Flow | N/A | $47.51M |
| Capital Expenditures | N/A | $-3.48M |
| Free Cash Flow | N/A | $58.37M |
| Debt Repayment | N/A | $-2.64M |
| Common Stock Repurchase | N/A | $-11.31M |
Short Interest & Institutional Ownership Analysis
| Metric | RGC | PBH |
|---|---|---|
| Shares Short | 1.68M | 1.51M |
| Short Ratio | 6.07 | 3.44 |
| Short % of Float | 0.02% | 0.04% |
| Average Daily Volume (10 Day) | 183,082 | 406,280 |
| Average Daily Volume (90 Day) | 247,494 | 411,937 |
| Shares Outstanding | 494.49M | 49.51M |
| Float Shares | 18.43M | 48.85M |
| % Held by Insiders | 0.96% | 0.01% |
| % Held by Institutions | 0.00% | 1.08% |
Dividend Analysis & Yield Comparison: Regencell Bioscience vs Prestige Consumer
| Metric | RGC | PBH |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |